In four independent databases consisting of a total of 581 ER+ breast cancer patients treated with TAM, higher pretreatment expression of VDR in the tumors was predictive of significantly longer RFS, compared with patients whose tumors expressed lower levels of VDR (Figure 1A–D). The gene discussed is ESR1; the disease is breast carcinoma.